Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04197986
Title	Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Acronym	PROOF302
Recruitment	Terminated
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	QED Therapeutics, Inc.
Indications	invasive bladder transitional cell carcinoma
Therapies	Infigratinib
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BGR \| BEL